Cellmyx

What Cellmyx does

Cellmyx (legally Millennium Medical Technologies Inc.) is a Carlsbad, California-based medical device manufacturer that designs, patents, and produces proprietary products for autologous adipose tissue transfer. The company's core offering is the IntelliFat BOD System, an FDA 510(k)-cleared medical device used by surgeons and medical facilities to harvest, process, and reinject a patient's own adipose tissue for cosmetic, plastic, and orthopedic surgical applications, including regenerative medicine procedures involving adipose-derived stem cell technologies. Cellmyx has focused exclusively on adipose tissue transfer technology for over 25 years, positioning itself as a domain specialist rather than a diversified medtech player, and operates under ISO 13485 quality management and Medical Device Single Audit Program (MDSAP) certifications.

The company sells to two primary customer segments: cosmetic and plastic surgery providers using adipose grafting for aesthetic and reconstructive procedures, and orthopedic surgery providers using the same technology for regenerative musculoskeletal treatments. Pricing is not publicly disclosed, and no distribution channels, named customers, or revenue figures are available in the source data; the company operates with 1–10 employees, which is consistent with a focused niche device manufacturer relying on specialized sales rather than broad commercial infrastructure. Leadership disclosed in the source material is limited to a Chief Scientific Officer (Wangzhong Sheng), with no broader management team, marketing, or go-to-motion structure described.

In June 2025, Cellmyx was acquired by Micro Imaging Technology Inc. (MIT), a California-based public company trading under the ticker MMTC. The transaction positioned Cellmyx's IntelliFat BOD technology alongside MIT's earlier SaltMed/SaltFacial acquisition, with the stated objective of strengthening manufacturing capabilities, expanding product offerings, and increasing reach in both domestic and international aesthetics and regenerative medicine markets. Following the acquisition, Cellmyx is reported to operate as part of MIT's combined medical aesthetics portfolio rather than as a standalone entity.

Name

Cellmyx

Legal name

Millennium Medical Technologies Inc.

Website

https://cellmyx.com

Company type

Private

Founded year

2000

Operating status

Acquired

Headcount range

1–10 employees

Short description

Cellmyx (Millennium Medical Technologies Inc.) is a Carlsbad, California-based medical device manufacturer that designs and produces the FDA 510(k)-cleared IntelliFat BOD System for autologous adipose tissue transfer in cosmetic, plastic, and orthopedic surgery. Founded around 2000, the company was acquired by Micro Imaging Technology (MMTC) in June 2025.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Autologous adipose grafting
• Regenerative medicine devices
• Fat transfer systems
• Medical device manufacturing
• Orthopedic cosmetic surgery

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Core offering

Cellmyx designs, patents, and manufactures the IntelliFat BOD System, an FDA 510(k)-cleared medical device for autologous adipose tissue harvesting, processing, and reinjection. The system supports adipose tissue transfer applications in orthopedic, plastic, and cosmetic surgery procedures, and underpins regenerative medicine use cases such as adipose-derived stem cell therapies.

Product overview

Cellmyx (operating as Millennium Medical Technologies Inc.) is a manufacturer specializing in autologous adipose grafting and transfer products for regenerative medicine, cosmetic surgery, and orthopedic applications. The company's core product is the FDA-cleared IntelliFat BOD system, which has been in operation for 25 years in the cosmetic surgery industry. Cellmyx focuses exclusively on adipose tissue transfer technology and regenerative medicine solutions.

Differentiator

Problem solved

Functional benefit

Brands

• intelliFat BOD: FDA-cleared device for autologous adipose grafting used in orthopedic and cosmetic surgery applications.

Products and services

• IntelliFat BOD System FDA 510(k)-cleared medical device for autologous adipose grafting and transfer, designed for use in orthopedic, plastic, and cosmetic surgery procedures. The system enables adipose tissue harvesting, processing, and reinjection for regenerative medicine applications and is intended for surgical practices performing fat transfer procedures.
• Autologous Adipose Grafting Products Medical devices and consumables for harvesting, processing, and transferring a patient's own adipose tissue for cosmetic and reconstructive procedures, supporting regenerative medicine applications across cosmetic, plastic, and orthopedic surgical settings.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Micro Imaging Technology (MIT)coreStrategic or Co-development Partner · 5 June 2026Micro Imaging Technology (MIT), a California-based public company trading as MMTC, acquired Cellmyx as part of its strategy to expand into the aesthetics and regenerative medicine sector. The acquisition combines Cellmyx's FDA-cleared IntelliFat BOD technology and 25-year expertise in adipose tissue transfer with MIT's existing SaltMed/SaltFacial portfolio. The combined entity aims to strengthen manufacturing capabilities, expand product offerings, and increase reach in domestic and international markets.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• MicroAire Surgical Instruments: MicroAire produces power-assisted liposuction and fat harvesting instrumentation used by plastic surgeons for autologous fat transfer procedures, competing head-to-head with Cellmyx's device in cosmetic and orthopedic fat grafting workflows.
• Puregraft: Puregraft makes a closed-system fat graft processing device for plastic and reconstructive surgery, directly comparable to Cellmyx's IntelliFat BOD in autologous adipose harvesting, washing, and reinjection workflows.
• Tulip Medical: Tulip Medical is a long-standing manufacturer of fat grafting cannulas, syringes, and accessories used by the same cosmetic and reconstructive surgery audience that buys Cellmyx's IntelliFat BOD.
• Human Med AG (Body-Jet): Human Med markets the Body-Jet water-assisted liposuction platform for gentle fat harvesting used in autologous fat transfer, a competing device to IntelliFat BOD for plastic and cosmetic surgeons performing fat grafting.
• Lipivage: Lipivage produces an autologous fat harvesting and transfer system targeted at cosmetic and reconstructive surgery, mirroring Cellmyx's core product niche of single-procedure adipose graft collection and reinjection.

Broad incumbents

• Mentor Worldwide (J&J MedTech): Mentor, part of J&J MedTech, supplies breast implants and a broad portfolio of aesthetic and reconstructive surgery products serving the same plastic and cosmetic surgery customers who purchase Cellmyx's IntelliFat BOD.
• Stryker: Stryker is a large orthopedic medtech incumbent with regenerative medicine and biologic adjacencies; it competes in the orthopedic surgery use case where Cellmyx's IntelliFat BOD is also indicated, but as part of a much broader portfolio.
• Alma Lasers: Alma Lasers offers a broader aesthetic device portfolio including body contouring and fat-related platforms sold into the same medical aesthetics clinics that purchase adipose transfer devices like the IntelliFat BOD.
• Zimmer Biomet: Zimmer Biomet is a major orthopedic and sports medicine incumbent with biologics and regenerative offerings, competing with Cellmyx in the orthopedic regenerative use case as part of a much wider surgical portfolio.

Others

• MTF Biologics: MTF Biologics is a tissue bank providing allogeneic and autologous biologic grafts, including adipose-derived products, used by the same surgeons who use Cellmyx's IntelliFat BOD but operating as a tissue supplier rather than a device manufacturer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellmyx